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Cardi,s transplantation is currently an accepted therapy fur 
intractable end stage hear? di\ea\e. Sesau\e Ihe wpplv of 
donor heati; is limited. analyst of morbid wenl) md 
identification of the rish factorr fcr premature death early 
and lilti after cardiac lranbplantation could have an impor- 
mnt role in identifying padents mosl hkcly 10 denve benefit 
from cardiac tmnsplantalion. This wdy wa undeflaken IO 
further evaluale new knowledge and txhnique, lbat could 
improve the read& o f ” d’*- !ransp!an!a!icn mr I.._ 
Methods 
Study patients. Belwren IYBi uinl wdiac wwrpi~nw 
lion on November 24. 19811 and July 1985. 61 patienl\ 
underwent cardiac rran\pl;mtatxun aL the Univentty of Aia- 
bamaal Birmingham. This waq an era of ready avmlabdlty of 
donor hearts and of exploration of the role of cardrac 
transplantation among the lhenpcutvz modalilx> of ad- 
vanced hew diseac. Of these 63 patienls, 60 underrvcnt 
primary urthutopac cardiac tranrplantnl~on ;mld 3 ~~nderweni 
hctcrorap~c Iran\pl;mtntion. SIX of the 63 patients underwent 
il vxond cardiac Iran~plentNion and I underwent P Ih;:d 
t~an~pkmtdlmn. The primary diagnori% WPS idiapathic cm- 
dlomyoparhy in 42 palienti lin 2. cardiomyopathy was 
a\rociatc*l wlh villvular heart d~scasc~. irchemx cardmm- 
yop&hy II IX and uncorrectable congeniml heart diqeax m 
3. The firrl 17 padents underwent cardiac tran~pkmtsiton 
with smlmuprine-baaed ~mmunorupprefcion. and the wbse- 
qucnt 46 pal~entr with cyclosporine.hased itmmtinosi;ppres- 
\,““. 
Dmmr heart procwemenl. Hearts were procured fron; 
local. re$mnal and distant area\ throughout lixi expcnence 
The man donor hean lrchemic time WIF I48 minutes (raw 
47 to 2%~ Slandard criteria wcrc used in \electmg appropn- 
iale donor heilns ,I-31. 
Operative teebnique. One liter of cold crystalloid hypcr- 
kalemic 00 mEq/lilerl cardioplegs \&lion was Infused at 
the time of donor heart barvertmg Topical coaling and 
axage in cold saline solution (5 10 6°C) were employed 
during Iran\portaiion. During implantation. hypothermic f?5 
to ?X”CI cardiopulmonmy hypars was utilized. and topical 
cardiac hypolhermia was msinlirined wth imermiltenl irri- 
gation uf the pericardial tpacc with cold wline calution. 
Ciwdmplcgw rcinfuriun wa\ not employed during impkmta- 
tion Orlholopic fran~planwion wa* performed by the tech- 
mquc dcxrihcd hg Loner and Shornway 141. and hctcrolo- 
pit cardox transplantation hy that dc\crihed hy Barnard. 
Nowisky and their colleagues 0.6). 
Immunnsuppression. A:efhinprir,P-hnscd inimrmxup- 
prmrimr included arathioprine 81 a dose of 2 mdkg body 
weight prcoperarwclg and a postoperative dose of 2 me/kg 
per day ndjustcd according 10 the white blood ccl’ counl. 
Methylprcdmsolone was adminiswed introoperatively (500 
mg at the conclusion of cardiopulmonrry bypass) and posl- 
operatively (125 mg every 8 h for three doses). Prednisone 
was m!tiatcd al a daily dose of I mglkg and Eradually tapered 
over 2 momhi to a dose of 0.2 mgikg per day. Rabbit 
antithymocyte globulin was adminialcred for IO to 14 days 
after trancplan&on. 
Cvc lospwiw-hosed ial,,tsrror,r~~rrnio,l included the 
ramc promu& for methylprednirolone and prcdniaone. Cy- 
closporme WBT adminiaered at a dose of IO to I2 mglkg 
orally hefore Iransplanlalion. and dopes were adjusted pat- 
opcraively 10 mainmin a whole blood cyclasporine level (by 
nd~o~mmunoars?y) of 5MI to 1.ooO nglml. After 3 momhs. 
the lcwl was gradually reduced to 250 Lo 500 ng’ml. Triple 
droptherapy with cyclorporine. azathioprine and prednisonc 
was not employed during this lime period. 
Rejection. Rejection episodes were identified in nearly all 
caseh hg endomyocardial biopsy and the patients were 
lrealed with transient augmenlalion of immunosuppression. 
In paliems given cyclosporine. rejection graded as moderate 
or severe on biopsy (7.81 always preceded treotmcm. 
Rejection wa; lrealed mlrially~with inlravenous m<!thyl- 
predzisolone. (1 8) daily. for 3 days. Amilhymocyte globulin 
was generally added if rejection I) persisted (as assessed by 
endomyocardial biopsy) after IWO courses of methylprednis- 
olone therapy. or 21 was accompanied by hemodynamic 
derangemems. A rejection episode was considered to have 
eodcd when rejection wes absent or mild on biopsy. Two 
episodes separated by only several days wcrc considered as 
one conlinuoos rejeciion episode. 
Infection. Aay infective episode requiring ho\pilaliration 
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fatal oulcome was considered a major infection. 
Cardiac failure. A clinical evem assocmled with signs of 
either :ou, cardiac outpul or symptomatic pulmonary venous 
hypcrlcnrion N>T termed acute cardiac fadure. lo addition, 
mearurcd cardiac index <? 0 liwnlmin per m” or the need 
forprcmer inotroptc wppon than lhat provided by dopamine 
during the first week cfter lranrplamation was termed acute 
cardiac bilure. Subacme cardiac failure was defined as low 
cardiac ouIput wh or wl:hw!t pulmonary venous hypenen- 
sion. documented by repcm..l right heart catheleraation and 
lkaling weks or m&lhr. 
Sudden death. Dcmh was defined a* cudden if it occurred 
unexpectedly and whom ldcntifiahlc precedmg signs of 
aCute cardmc failure. uwally whde the patienl was out ofthe 
hoap&d. 
Renal failure. Rcn..l failure was defined hy serum crest- 
ioine levc!* >2.0 mgilM~ ml or the need for dmlysis. or both. 
Delinition of postoperative events. A cause of death WBI 
asslgned to each patient who died during the study period. 
Whenever possible, Ihe assigned cause was based on au- 
topsy findings; when these were nor available. il E~USC was 
assigned after review of all clinical, biopsy and culmre 
information available hefore death. Erenls associated with 
morbidity (morbid events) were idemified for each patient 
wer the period of follow-up study. Deaths occurring during 
a morbid event (but not necessarily caused by lhal event) 
were also lahulated. 
Pulmonary vascular resistance. Calculation of the pulmo- 
nary vascular resistaxe (PVR) index (unitsm’) was made 
by the following formula: 
Mea” pulmonary artery pEESUre - Left atria, pressure 
Cardmc index 
= PYR. 
Mean pulmonary artery IPA) pressure was determined elec- 
tronically or by the formula: PA mean = PA diastolic + [(PA 
sysro!l- - PA diastolic)/3]. If left atrial pressure was not 
available, the pulmonary capillary wedge pressure was used. 
The v&e used in all analyses was that obtained closest to 
the lime of transplantation without specific attempts at 
modification by vasodilator therapy. 
Follow-up studies. All surviving patients were seen peri- 
odically in follow-up, except for two patients who underwent 
long-term follow up in another institution. Additional details 
were obtained by correspondence with the patients’ physi- 
cian. Follow-up was completed through December31. I985 
for all morbid events and through July I, 1986 for survival. 
Data analysis. The usual contingency tables and melhods 
for eslimating the bkebhood that diflerences were due to 
chance were used. Survival and freedom from other adverse 
events were described in a lime-related manner actuarially. 
parametrically and by a depiction of the instantaneous risk of 
the event at all points in lime afier the operation (9). Factors 
that increased the risk of death were identified by mulliva- 
riate analysis in Ihe hazard domain. Tbe variables entered in 
the risk factor analysi> for death are given in the Appendix. 
Results 
Survival. Among the 63 patients. 29 deaths occurred by 
July I, 1986. The actuarial survival was 71.51 and 48% at I. 
2 and 3 years after transplanration. respectively (Fig. I j. The 
hazard function for death was highest immediately after 
operation and declined rapidly thereafter to merge with the 
constant phase of hazard by about 3 monlhs postoperatively 
(Fig. 2). 
Causes of death (Table I,. The most comma” C!IXY of 
death were acute cardiac rejection and infecnon. which 
accounted for 41% of the demhs. Four of the six patienls 
who died inlraoper~tivel~~ devcloped uxversible right ven- 
tricular failure in the setting of marked mtraoperative In = II 
or preoperative (n = 3) pulmonary hypertension. Two of the 
six patients died with acute cardiac failure associated wth 
destabilizing intraoperative bleeding. One of these, who 
underwent heterotopic transplantation. had sewre bleeding 
through the interstices of the tube graft to the pulmonary 
artery; the other. with uncorrectable congenital hean dis- 
ease. had undergone seven previous cardiothoncic open- 
lions including a modified Fontan prxedure. 
Riskfaclols for death (Tabk2). Immunologic intolerance 
of the transplanted heart is obviously the most powerful risk 
factorfordeath. However, amongthe preoperative vartaales 
avadable for multivanate ,nalyvr. only three were identified 
anh reasonable certainty Cp d 0.1) ac bang r!Tk factors. htgh 
pulmonary vascular resistance. black race and morphology 
of cardiomyopathy. The e&ct of pulmonary vascular reiis- 
tsnce CBC a1w evident on simple analysis (Fig. 3). White 
patients wth tschemic heart disease and low pulmonary 
va~c~dw rev~tance are prcdlctcd to have the most favornh!e 
intermsdiatr-term survival afterwrdiac transplantation (Fig. 
4). Such pat!ents with a pulmonary vascular resistance <3 
units-m had geater than 85% chance of wrvivmg Z years 
after tranrplantation. 
The immunosuppressi~x era was not a risk factor on 
multivariate analysis. but patients undergoing orthotopic 
transplantation who were maintained on cycloqnxine and 
predniwne lwtbout cowerston to azathmprine or discontin- 
uation ofqcloaporinc) had an actuanal survival ntc of 79% 
nt I year nd 68% to 2 yeas of follow-uo. which was nearly 
tranrplantation, and the other IS well 2 year, aftertransplan- 
tation. 
Morbid events (Tables 3 to 5). Morbid events were com- 
mon after cardiac transplantstian. with multiple events oc- 
curring in many patientr (Table 3). Fifty-one episodes of 
cardiac failure occurred. ofwhich 31% were associated with 
a la, d ~ulnwnr Fifty percent of patients had one or more 
episodes of cardiac failure within the first 1 months after 
tmnsplantation. The incidence of cardiac fadure was highw 
early after operation. with no further episodes after I5 
months. Twenty perccni of the episodes of aeutc carduc 
failure wcrc associated wilh acuLc rejec!io” ldelermined by 
biopsy or autopsy). None of the 25 eplsades of acute carllrac 
failure occurring m the first 10 dayc after trancpiantation 
WC?~ associated with rejection, whereas 50% (8 of !6) of 
such episodes thereafter were rejection related II) for diffcr- 
ence = ll.llcHll). 
Thirty-fonr of r/w 63 p&errrs e.~perirtrt rd 49 UCIIIY re~rr- 
lion episodes ITablc 4). Over 5% of all rejection cpiwdes 
were Jclcctcd during a routine biopsy lrithoul other signr or 
sjympioms suggcslmg rejection (Table 4). The hazard func- 
bon for the first acute rejection episode mc:eased from L low 
level early after transplantation lo a peak at approximately I 
month after transplantation (Fig. 6). The incidence of rqcc- 
Lion episodes/month per patient declined from 0.44 during 
the first month fo 0.18 during the second month: thereafter. 
poncnd a Ica favorable outcome t1.G1%. Our finding that 
the time period of greatest ribk is early after transplantation 
is in keeping with other reports 120). and underscorec the 
unportance of avoiding potentially preventohle causes of 
early morrahry if late WYIV~I i)l to be improved. kletler 
method\ of donor hean preservation (possibly including 
multidose oxygenacd &dioptegia during implantation 
[21.2?1 and controlled reperfusion with nurmothermic by- 
perkalcmic blood 123.241) and avoidance of serious intraop- 
er~twc hemorrhage m the presence of multiple previous 
sicrnotomir\ may lessen this early mortality. 
The consmnl phax ofbazxd (risk) for patients undergo- 
ing cardiac wamplantation (0.02 death.monthK’) i> greater 
than Ihc constanl phase halard of 0.009 for pauen& with an 
cjectmn Inchan of IS% undergoing primq coronary by- 
pass surgery 81 our institution from 1977 to 1981 1751. This 
?~uggcst\ that most pat~ntr with severe left ventricular 
dysfunc:lon 2nd wcrc awciated cormwy artery disease 
wthoul * priur ~~~~~orny should undergo coronary revas- 
culariLatlon rather than initial tranrplanlarion. 
Risk Letm for death. Subtle immunologic factors that 
predict irreversible rejection of the transplanted heart would 
likely represent the most powerful risk factors for premature 
death if they could be identified. In this study. the only 
immunologic variable entered into the multivariate analysis 
was human leukocyte antigen (HLA) compatibility and that 
was ilot significantly related to early or intermediate SUP 
vivaI. 
Eicwred p,t I,,, onqv wscrrhr wsisrnncc has long been 
identified as an important risk factor (though with limited 
published data) foor ea:ly cardiac failure (26). and it was the 
preoperative risk factor associated with early mortality in this 
expenence. In view of the progressive increase in mortality 
with increasing pulmonary vascular resistance, sprclal cau- 
tion is advisable when considering padenrs For transplantation 
with even moderate elevation of pulmonary vascular resis- 
tance. At the time of transplantation. it may be beneficial to 
select a larger donor hecln wth a shorter ischemic time for 
recipienls with elevated pulmonary vascul~ resistance to 
maximize the likelihood of robust right ventricular function. 
Heterotopic cardiac tramplantation may aIs0 be cmsidered 
for patients with elevated pulmonary vtwular rccistance. but 
the survival rates of the few such patientc reported here and 
the overall survival rates reported in the Registry of the 
lntemational SCrty for Heafi Transplan~tion 120) arc gcn- 
crally ksb pwd than thuss fur ortbotopic trdnsplantdtion. The 
erplanation fw increased pulmonary vxcuI~r resistance be- 
ing a risk factor in the constant phase remains obscure 
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